Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Wayne Yeh, M.D.

Co-Author

This page shows the publications co-authored by Robert Yeh and Sharon-Lise Normand.
Connection Strength

2.927
  1. Yeh RW, Mauri L, Wolf RE, Romm IK, Lovett A, Shahian D, Normand SL. Population trends in rates of coronary revascularization. JAMA Intern Med. 2015 Mar; 175(3):454-6.
    View in: PubMed
    Score: 0.691
  2. Yeh RW, Rosenfield K, Zelevinsky K, Mauri L, Sakhuja R, Shivapour DM, Lovett A, Weiner BH, Jacobs AK, Normand SL. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. Circ Cardiovasc Interv. 2012 Apr; 5(2):227-36.
    View in: PubMed
    Score: 0.563
  3. Hawkins BM, Kennedy KF, Aronow HD, Nguyen LL, White CJ, Rosenfield K, Normand ST, Spertus JA, Yeh RW. Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv. 2015 May; 8(6):858-863.
    View in: PubMed
    Score: 0.175
  4. Yeh RW, Czarny MJ, Normand SL, Kereiakes DJ, Holmes DR, Brindis RG, Weaver WD, Rumsfeld JS, Roe MT, Kim S, Driscoll-Shempp P, Mauri L. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):96-102.
    View in: PubMed
    Score: 0.169
  5. Wasfy JH, Strom JB, Waldo SW, O'Brien C, Wimmer NJ, Zai AH, Luttrell J, Spertus JA, Kennedy KF, Normand SL, Mauri L, Yeh RW. Clinical preventability of 30-day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014 Sep 26; 3(5):e001290.
    View in: PubMed
    Score: 0.168
  6. Wasfy JH, Strom JB, O'Brien C, Zai AH, Luttrell J, Kennedy KF, Spertus JA, Zelevinsky K, Normand SL, Mauri L, Yeh RW. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Feb; 7(1):97-103.
    View in: PubMed
    Score: 0.160
  7. Yeh RW, Vasaiwala S, Forman DE, Silbaugh TS, Zelevinski K, Lovett A, Normand SL, Mauri L. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):118-24.
    View in: PubMed
    Score: 0.158
  8. Wasfy JH, Rosenfield K, Zelevinsky K, Sakhuja R, Lovett A, Spertus JA, Wimmer NJ, Mauri L, Normand SL, Yeh RW. A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):429-35.
    View in: PubMed
    Score: 0.154
  9. Amin AP, Spertus JA, Cohen DJ, Chhatriwalla A, Kennedy KF, Vilain K, Salisbury AC, Venkitachalam L, Lai SM, Mauri L, Normand SL, Rumsfeld JS, Messenger JC, Yeh RW. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012 Aug 13; 172(15):1145-52.
    View in: PubMed
    Score: 0.145
  10. Kunz LM, Yeh RW, Normand SL. Comparative effectiveness research: does one size fit all? Stat Med. 2012 Nov 10; 31(25):3062-5; discussion 3066-7.
    View in: PubMed
    Score: 0.144
  11. Yeh RW, Normand SL, Wang Y, Barr CD, Dominici F. Geographic disparities in the incidence and outcomes of hospitalized myocardial infarction: does a rising tide lift all boats? Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):197-204.
    View in: PubMed
    Score: 0.140
  12. Yeh RW, Normand SL, Wolf RE, Jones PG, Ho KK, Cohen DJ, Cutlip DE, Mauri L, Kugelmass AD, Amin AP, Spertus JA. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.136
  13. Kumar A, Matheny ME, Ho KK, Yeh RW, Piemonte TC, Waldman H, Shah PB, Cope R, Normand SL, Donnelly S, Robbins S, Resnic FS. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):38-46.
    View in: PubMed
    Score: 0.043
  14. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.042
  15. Matteau A, Yeh RW, Kereiakes D, Orav EJ, Massaro J, Steg PG, Normand SL, Cutlip DE, Mauri L. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.